Genmab reaches first milestone in HuMax-TAC agreement with Serono
In May 2005, Serono and Genmab signed an agreement under which Genmab granted Serono exclusive worldwide rights to develop and commercialize Genmab's HuMax-TAC. Under the agreement, Genmab received an upfront payment of USD 2 million and is entitled to potential milestone payments of up to USD 38 million and royalties on sales from any eventual commercialization of the product. Serono is responsible for all future development for HuMax-TAC.
HuMax-TAC is a fully human monoclonal antibody that may have therapeutic potential in the treatment of T-cell mediated diseases, such as autoimmune disorders, inflammatory and hyperproliferative skin disorders, as well as transplant rejection. HuMax-TAC is currently in pre-clinical trials.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.